|
|
|
| Clinical efficacy of atorvastatin calcium tablets combined with sacubitril/valsartan in patients with chronic heart failure |
| ZHANG Ziyu1, WEN Juan2, XIE Fen2, PENG Hongying2, Duan Wen2, YU Caihong1,2 |
1. School of Medicine Hunan Normal University, Changsha 410013;
2. Sanzhen Rehabilitation Hospital in Changsha, Hunan Province, Changsha 410006 |
|
|
|
|
Abstract Objective The aim of this report is to explore the effects of atorvastatin calcium tablets combined with sacubitril/valsartan on clinical efficacy, cardiac color ultrasound indexes and serum indexes in patients with chronic heart failure. Methods We collected data of 87 patients with chronic heart failure admitted to Sanzhen Rehabilitation Hospital in Changsha, Hunan Province from January 2022 to December 2022. According to the random number table method, the patients were divided into control group (treated with atorvastatin calcium tablets orally and diuretics, etc. ) with 43 cases and observation group (treated with sacubitril/valsartan plus the same therapy as the control group) with 44 cases. Results were compared between the two groups, including post-therapy efficacy and readmission rates, cardiac ultrasound and serum indexes before and after treatment, and the occurrence of adverse reactions during treatment. Results After 2 months of treatment, the total clinical efficiency of the observation group was 95.45%, which was significantly higher than that of the control group (74.42%). And the overall incidence of adverse reactions and the readmission rate of the observation group were observably lower than those of the control group. Compared with the pre-therapy period, an increase of various indicators was significantly obvious in both groups after treatment, including left ventricular ejection fraction (LVEF), systolic peak velocity (SPV), left anterior descending branch diastolic peak velocity (DPV) and time velocity integral (TVI). And the changes in the observation group were signally more obvious than the control group, with statistically significant differences between the two groups. Both of the two groups had an evident decrease in the left ventricular end-systolic diameter (LVESD) and the left ventricular end-diastolic diameter (LVEDD). And the LVESD and LVEDD were lower in the observation group than in the control group. However, there was no statistically significant difference in LVEDD level through the intra-group comparison of the control group before and after treatment. Conclusion Atorvastatin calcium tablets combined with sacubitril/valsartan has a good application effect in patients with chronic heart failure, as it apparently contributes to improving the prognosis and enhancing the quality of their lives.
|
|
Received: 19 August 2023
|
|
|
|
|
|
[1] UNGER T, BORGHI C, CHARCHAR F, et al.2020 International Society of Hypertension Global Hypertension Practice Guidelines[J]. Hypertension, 2020, 75(6): 1334-1357.
[2] 孙明. 不同种类他汀药物在慢性心力衰竭治疗中的作用比较[J]. 现代诊断与治疗, 2022, 33(20): 3091-3093.
[3] 杨静, 裴双义, 朱丹, 等. 沙库巴曲缬沙坦联用丹参川芎嗪改善慢性心力衰竭患者左心功能和NT-ProBNP. MMP-9水平[J]. 中国新药与临床杂志, 2019, 38(8): 493-498.
[4] 葛均波, 徐永健, 王辰. 《内科学》(第九版)[M]. 北京: 人民卫生出版社, 2019, 168.
[5] 胡保奎, 王玮, 戴敏. 沙库巴曲缬沙坦钠片联合阿托伐他汀钙片治疗高血压合并冠心病的临床研究[J]. 中西药结合心脑血管病杂志, 2023, 21(17): 3217-3220.
[6] 刘冰. 氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的疗效和不良反应分析[J]. 中国实用医药, 2023, 18(12): 108-110.
[7] 刘焰华, 李枫, 汪蛟龙, 等. 沙库巴曲缬沙坦治疗慢性心力衰竭[J]. 长春中医药大学学报, 2019, 35(3): 457-460.
[8] 戴雯莉, 吴翔宇, 王苏, 等. 沙库巴曲缬沙坦治疗慢性充血性心力衰竭患者的临床研究[J]. 中国医药, 2019, 14(9): 1297-1301.
[9] 何涛, 邓学军, 何小君, 等.丹参酮ⅡA磺酸钠联合瑞舒伐他汀治疗慢性心力衰竭的效果及其对血流动力学和心室重构的影响[J]. 现代医学, 2019, 48(5): 561-565.
[10] 陈莉, 逯伟达, 吴媛媛, 等. 沙库巴曲缬沙坦对射血分数降低的心力衰竭IV级患者生化指标和左心室结构的干预作用[J]. 中华老年医学杂志, 2019, 38(5): 525-528. |
|
|
|
2023, Vol. 20 
